Table 1 Characteristics of case-control studies about FeNO
From: Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis
Year | Author | Country | Age matched | Sex matched | Smoking matched | Histology | Stage | FeNO (ppb) | NOS | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Case | |||||||||||
Mean ± SD | n | Mean ± SD | n | |||||||||
1998 | Liu | China | NA | Yes | Yes | SCC, ADC, LCC, SCLC | advanced | 6.0 ± 0.5 | 20 | 16.9 ± 0.9 | 28 | 7 |
2001 | Koizumi | Japan | NA | NA | NA | SCC, ADC, LCC, SCLC | early + advanced | 44 ± 13 | 11 | 77 ± 47 | 29 | 5 |
2005 | Masri | USA | NA | NA | NA | mixed (mainly SCC, ADC) | NA | 7.4 ± 0.54 | 35 | 18.4 ± 3.16 | 11 | 5 |
2016 | Xu | China | Yes | Yes | Yes | SCC, ADC, SCLC | early + advanced | 16.12 ± 5.85 | 51 | 25.60 ± 16.93 | 61 | 9 |
2018 | Feng | China | Yes | Yes | Yes | SCC, ADC, SCLC | NA | 16.8 ± 4.1 | 50 | 33.8 ± 15.6 | 50 | 8 |
2018 | Liu | China | Yes | Yes | NA | SCC, ADC, SCLC | NA | 16.83 ± 4.17 | 172 | 33.85 ± 15.63 | 164 | 8 |